Ina Laura Perkins

Ina Laura Perkins has worked in the healthcare and biomedical science industry since 2007. Ina Laura began their career as a Visiting Researcher at Ionis Pharmaceuticals, Inc., where they conducted their master's thesis project in microRNA research. In 2008, they were a Consultant at the Emerging Technologies Office of Hoffmann-La Roche, where they identified disruptive technologies with potential to fulfil critical medical needs. That same year, they also founded and co-CEO'd Visidence, a company that sought to enable prognosis of Graft versus Host Disease after haematopoietic stem cell transplants. From 2009 to 2013, they held various roles at Celixir, including Product Development - Industrial PhD Student and Head of Business Development. Finally, from 2017 to present, they have been Chief Executive Officer, Chief Scientific Officer, and Vice President of Translational Research at Scandinavian Real Heart. Additionally, from 2013 to 2017, they were Scientific Research Manager at Calon Cardio-Technology Ltd, where they managed pre-clinical testing of a novel heart pump and the biomedical science team.

Ina Laura Perkins completed a Master of Business Administration - MBA in Financial Management from the Stockholm School of Economics in 2019. Ina Laura also holds an MSc in Biomedicine from the Karolinska Institutet, an MSc in Innovation & Entrepreneurship with a special focus on biomedical innovations from the Chalmers University of Technology, and a Doctor of Philosophy (PhD) in Medicine from Swansea University.